| Assay ID | Title | Year | Journal | Article |
|---|
| AID1204386 | Antibacterial activity against Escherichia coli assessed as growth inhibition at 100 umol/L after 8 hrs by ELISA plate reader analysis relative to control | 2015 | European journal of medicinal chemistry, Jun-05, Volume: 97 | Benzaldehyde Schiff bases regulation to the metabolism, hemolysis, and virulence genes expression in vitro and their structure-microbicidal activity relationship. |
| AID644764 | Cytotoxicity against human MCF7 cells assessed as cell viability after 48 hrs by MTT assay | 2012 | European journal of medicinal chemistry, Mar, Volume: 49 | Synthesis, characterization and antiamoebic activity of some hydrazone and azole derivatives bearing pyridyl moiety as a promising heterocyclic scaffold. |
| AID1668222 | Inhibition of Electrophorus electricus AChE at 100 uM using acetylthiocholine iodide as substrate preincubated for 30 mins followed by substrate addition and measured after 10 mins by Ellman's method (Rvb = 7 +/- 7.1%) | 2020 | Bioorganic & medicinal chemistry, 05-15, Volume: 28, Issue:10
| Acylhydrazones as isoniazid derivatives with multi-target profiles for the treatment of Alzheimer's disease: Radical scavenging, myeloperoxidase/acetylcholinesterase inhibition and biometal chelation. |
| AID1488825 | Half-life in RPMI media at 100 uM | 2017 | Bioorganic & medicinal chemistry letters, 09-01, Volume: 27, Issue:17
| The hydrolytic susceptibility of prochelator BSIH in aqueous solutions. |
| AID644763 | Antiameobic activity against Entamoeba histolytica HM-1:IMSS after 72 hrs using trypan blue staining method | 2012 | European journal of medicinal chemistry, Mar, Volume: 49 | Synthesis, characterization and antiamoebic activity of some hydrazone and azole derivatives bearing pyridyl moiety as a promising heterocyclic scaffold. |
| AID1893802 | Induction of apoptosis in human A2780 cells assessed as early apoptosis level at 20 uM incubated for 48 hrs by PI and FITC-Annexin V staining based flow cytometry | 2022 | ACS medicinal chemistry letters, Sep-08, Volume: 13, Issue:9
| Aroylhydrazone Glycoconjugate Prochelators Exploit Glucose Transporter 1 (GLUT1) to Target Iron in Cancer Cells. |
| AID1204388 | Antibacterial activity against Staphylococcus aureus assessed as growth inhibition at 100 umol/L after 8 hrs by ELISA plate reader analysis relative to control | 2015 | European journal of medicinal chemistry, Jun-05, Volume: 97 | Benzaldehyde Schiff bases regulation to the metabolism, hemolysis, and virulence genes expression in vitro and their structure-microbicidal activity relationship. |
| AID1204387 | Antibacterial activity against Bacillus subtilis assessed as growth inhibition at 100 umol/L after 8 hrs by ELISA plate reader analysis relative to control | 2015 | European journal of medicinal chemistry, Jun-05, Volume: 97 | Benzaldehyde Schiff bases regulation to the metabolism, hemolysis, and virulence genes expression in vitro and their structure-microbicidal activity relationship. |
| AID1317549 | Iron chelating activity assessed as Fe3+-compound complex-induced antioxidant activity by measuring ascorbate oxidation level at iron binding equivalent of 3 measured after 10 to 40 mins in presence of 500 uM of citrate relative to control | 2016 | European journal of medicinal chemistry, Sep-14, Volume: 120 | Aroylhydrazone iron chelators: Tuning antioxidant and antiproliferative properties by hydrazide modifications. |
| AID1317558 | Protection against t-BHP-induced oxidative injury in rat H9c2 cells assessed as increase in cell viability incubated for 10 mins followed by stimulation with t-BHP for 24 hrs by neutral red staining based assay | 2016 | European journal of medicinal chemistry, Sep-14, Volume: 120 | Aroylhydrazone iron chelators: Tuning antioxidant and antiproliferative properties by hydrazide modifications. |
| AID1488826 | Stability of the compound in aqueous solvent at 500 uM after 24 hrs in presence of H2O2 by 1H-NMR spectroscopic analysis | 2017 | Bioorganic & medicinal chemistry letters, 09-01, Volume: 27, Issue:17
| The hydrolytic susceptibility of prochelator BSIH in aqueous solutions. |
| AID1488811 | Stability of the compound in minimal essential medium assessed as compound hydrolysis at 100 uM at pH 7.4 after 24 hrs by UV-Vis spectrophotometric analysis | 2017 | Bioorganic & medicinal chemistry letters, 09-01, Volume: 27, Issue:17
| The hydrolytic susceptibility of prochelator BSIH in aqueous solutions. |
| AID1419221 | Cytotoxicity against human ARPE19 cells up to 100 uM after 24 hrs by CellTiter-Blue assay | 2018 | Bioorganic & medicinal chemistry, 12-01, Volume: 26, Issue:22
| Modifying aroylhydrazone prochelators for hydrolytic stability and improved cytoprotection against oxidative stress. |
| AID1179730 | Cytoprotection in mouse CRL2181 cells assessed as reduction in UV-oxidized LDL-induced cytotoxicity by measuring cell viability at 10 uM after 24 hrs by MTT assay relative to untreated control | 2014 | Bioorganic & medicinal chemistry, Aug-01, Volume: 22, Issue:15
| Synthesis, antioxidant and cytoprotective evaluation of potential antiatherogenic phenolic hydrazones. A structure-activity relationship insight. |
| AID1317553 | Cytotoxicity against rat H9c2 cells assessed as decrease in cell viability after 72 hrs by neutral red staining based assay | 2016 | European journal of medicinal chemistry, Sep-14, Volume: 120 | Aroylhydrazone iron chelators: Tuning antioxidant and antiproliferative properties by hydrazide modifications. |
| AID1179727 | Antioxidant activity assessed as DPPH radical scavenging activity by UV-Visible spectrophotometry | 2014 | Bioorganic & medicinal chemistry, Aug-01, Volume: 22, Issue:15
| Synthesis, antioxidant and cytoprotective evaluation of potential antiatherogenic phenolic hydrazones. A structure-activity relationship insight. |
| AID1668220 | Inhibition of rat bone marrow myeloperoxidase using H2O2 as substrate at 10 uM after 20 mins by TMB based method (Rvb = - 1.4 +/- 12.7%) | 2020 | Bioorganic & medicinal chemistry, 05-15, Volume: 28, Issue:10
| Acylhydrazones as isoniazid derivatives with multi-target profiles for the treatment of Alzheimer's disease: Radical scavenging, myeloperoxidase/acetylcholinesterase inhibition and biometal chelation. |
| AID1317554 | Cytotoxicity against human MCF7 cells assessed as decrease in cell viability after 72 hrs by neutral red staining based assay | 2016 | European journal of medicinal chemistry, Sep-14, Volume: 120 | Aroylhydrazone iron chelators: Tuning antioxidant and antiproliferative properties by hydrazide modifications. |
| AID1444593 | Inhibition of bovine xanthine oxidase using xanthine as substrate preincubated for 10 mins followed by substrate addition measured for 15 mins by spectrophotometric method | 2017 | Bioorganic & medicinal chemistry, 04-15, Volume: 25, Issue:8
| Xanthine oxidase inhibitory activity of nicotino/isonicotinohydrazides: A systematic approach from in vitro, in silico to in vivo studies. |
| AID258360 | Growth inhibition of chloroquine-resistant Plasmodium falciparum FcB1 at 1 uM | 2006 | Bioorganic & medicinal chemistry letters, Jan-01, Volume: 16, Issue:1
| Design, synthesis and in vitro antimalarial activity of an acylhydrazone library. |
| AID1332962 | Antitubercular activity against Mycobacterium tuberculosis H37Rv ATCC 27294 after 7 days by REMA method | 2016 | European journal of medicinal chemistry, Nov-10, Volume: 123 | Synthesis and biological activity of furoxan derivatives against Mycobacterium tuberculosis. |
| AID1419233 | Iron chelating activity of the compound assessed as recovery of calcein fluorescence from calcein-Fe3+ complex by measuring iron binding constant at 4 uM measured after 2 hrs by fluorescence assay | 2018 | Bioorganic & medicinal chemistry, 12-01, Volume: 26, Issue:22
| Modifying aroylhydrazone prochelators for hydrolytic stability and improved cytoprotection against oxidative stress. |
| AID1419215 | Iron chelating activity of the compound assessed as recovery of calcein fluorescence from calcein-Fe3+ complex by measuring iron binding constant at 4 uM preincubated with H2O2 for 12 hrs followed by addition to calcein-Fe3+ complex measured after 2 hrs b | 2018 | Bioorganic & medicinal chemistry, 12-01, Volume: 26, Issue:22
| Modifying aroylhydrazone prochelators for hydrolytic stability and improved cytoprotection against oxidative stress. |
| AID1668218 | Antioxidant activity assessed as DPPH radical scavenging activity at 100 uM after 30 mins (Rvb = 1.9 +/- 1.2%) | 2020 | Bioorganic & medicinal chemistry, 05-15, Volume: 28, Issue:10
| Acylhydrazones as isoniazid derivatives with multi-target profiles for the treatment of Alzheimer's disease: Radical scavenging, myeloperoxidase/acetylcholinesterase inhibition and biometal chelation. |
| AID1488823 | Drug metabolism in RPMI media assessed as equilibrium hydrolysis constant at 100 uM | 2017 | Bioorganic & medicinal chemistry letters, 09-01, Volume: 27, Issue:17
| The hydrolytic susceptibility of prochelator BSIH in aqueous solutions. |
| AID1317556 | Selectivity index, ratio of IC50 for rat H9c2 cells to IC50 for human MCF7 cells | 2016 | European journal of medicinal chemistry, Sep-14, Volume: 120 | Aroylhydrazone iron chelators: Tuning antioxidant and antiproliferative properties by hydrazide modifications. |
| AID1488850 | Cytotoxicity against human ARPE19 cells assessed as reduction in cell viability at 100 uM after 72 hrs by CellTiter-blue assay relative to control | 2017 | Bioorganic & medicinal chemistry letters, 09-01, Volume: 27, Issue:17
| The hydrolytic susceptibility of prochelator BSIH in aqueous solutions. |
| AID1317547 | Induction of transferrin labeled 59Fe mobilization in human MCF7 cells assessed as cellular 59Fe released at 25 uM after 3 hrs by gamma scintillation counting analysis (Rvb = 11%) | 2016 | European journal of medicinal chemistry, Sep-14, Volume: 120 | Aroylhydrazone iron chelators: Tuning antioxidant and antiproliferative properties by hydrazide modifications. |
| AID1488821 | Cytoprotective activity against H2O2-induced toxicity in human ARPE19 cells pretreated for 5 hrs followed by H2O2 addition after 19 hrs by CellTiter-blue assay | 2017 | Bioorganic & medicinal chemistry letters, 09-01, Volume: 27, Issue:17
| The hydrolytic susceptibility of prochelator BSIH in aqueous solutions. |
| AID1893803 | Induction of apoptosis in human A2780 cells assessed as late apoptosis level at 20 uM incubated for 48 hrs by PI and FITC-Annexin V staining based flow cytometry | 2022 | ACS medicinal chemistry letters, Sep-08, Volume: 13, Issue:9
| Aroylhydrazone Glycoconjugate Prochelators Exploit Glucose Transporter 1 (GLUT1) to Target Iron in Cancer Cells. |
| AID1179728 | Antioxidant activity assessed as reduction in mouse CRL2181 cells-mediated human LDL oxidation by measuring TBARS level at 10 uM after 18 hrs | 2014 | Bioorganic & medicinal chemistry, Aug-01, Volume: 22, Issue:15
| Synthesis, antioxidant and cytoprotective evaluation of potential antiatherogenic phenolic hydrazones. A structure-activity relationship insight. |
| AID1488835 | Drug level treated with BSIH in DMSO assessed as metabolite formation at 100 uM at pH 7.4 after overnight incubation in presence of H2O2 by UV-vis spectrometric analysis | 2017 | Bioorganic & medicinal chemistry letters, 09-01, Volume: 27, Issue:17
| The hydrolytic susceptibility of prochelator BSIH in aqueous solutions. |
| AID1488810 | Stability of the compound in phosphate buffered saline at pH 7.4 assessed as compound hydrolysis at 100 uM after 24 hrs by UV-Vis spectrophotometric analysis | 2017 | Bioorganic & medicinal chemistry letters, 09-01, Volume: 27, Issue:17
| The hydrolytic susceptibility of prochelator BSIH in aqueous solutions. |
| AID1179729 | Antioxidant activity assessed as reduction in mouse CRL2181 cells-mediated human LDL oxidation by measuring TBARS level at 1 uM after 18 hrs | 2014 | Bioorganic & medicinal chemistry, Aug-01, Volume: 22, Issue:15
| Synthesis, antioxidant and cytoprotective evaluation of potential antiatherogenic phenolic hydrazones. A structure-activity relationship insight. |
| AID1317548 | Inhibition of 59Fe uptake in human MCF7 cells labeled with 59Fe transferrin at 25 uM after 3 hrs relative to control | 2016 | European journal of medicinal chemistry, Sep-14, Volume: 120 | Aroylhydrazone iron chelators: Tuning antioxidant and antiproliferative properties by hydrazide modifications. |
| AID1317557 | Selectivity index, ratio of IC50 for rat H9c2 cells to IC50 for human HL60 cells | 2016 | European journal of medicinal chemistry, Sep-14, Volume: 120 | Aroylhydrazone iron chelators: Tuning antioxidant and antiproliferative properties by hydrazide modifications. |
| AID1317555 | Cytotoxicity against human HL60 cells assessed as decrease in cell viability after 72 hrs by MTT assay | 2016 | European journal of medicinal chemistry, Sep-14, Volume: 120 | Aroylhydrazone iron chelators: Tuning antioxidant and antiproliferative properties by hydrazide modifications. |
| AID1179731 | Cytoprotection in mouse CRL2181 cells assessed as reduction in UV-oxidized LDL-induced cytotoxicity by measuring cell viability at 1 uM after 24 hrs by MTT assay relative to untreated control | 2014 | Bioorganic & medicinal chemistry, Aug-01, Volume: 22, Issue:15
| Synthesis, antioxidant and cytoprotective evaluation of potential antiatherogenic phenolic hydrazones. A structure-activity relationship insight. |
| AID1488846 | Stability of the compound in minimal essential medium assessed as compound hydrolysis at 100 uM within 1 hr by UV-Vis spectrophotometric analysis | 2017 | Bioorganic & medicinal chemistry letters, 09-01, Volume: 27, Issue:17
| The hydrolytic susceptibility of prochelator BSIH in aqueous solutions. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
| Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1
| High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID1745846 | Firefly Luciferase Counterscreen for Inhibitors of ATXN expression | | | |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
| Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1
| High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
| Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1
| High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | | | |
| AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7
| A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID1745849 | Viability Counterscreen for CMV-Luciferase Assay of Inhibitors of ATXN expression | | | |
| AID1745850 | Viability Counterscreen for Confirmatory qHTS for Inhibitors of ATXN expression | | | |
| AID1745848 | Confirmatory qHTS for Inhibitors of ATXN expression | | | |
| AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7
| A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID1745847 | CMV-Luciferase Counterscreen for Inhibitors of ATXN expression | | | |
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | | | |
| AID504749 | qHTS profiling for inhibitors of Plasmodium falciparum proliferation | 2011 | Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
| Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets. |
| AID1347096 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347092 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347100 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1296008 | Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening | 2020 | SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
| Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening. |
| AID1347108 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347094 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347425 | Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1) | 2019 | The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
| Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens. |
| AID1347086 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1347093 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347091 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347424 | RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1) | 2019 | The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
| Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens. |
| AID1347103 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347099 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347105 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347083 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1347407 | qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection | 2020 | ACS chemical biology, 07-17, Volume: 15, Issue:7
| High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle. |
| AID1347102 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347106 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347104 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347082 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1347095 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347107 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347097 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1508630 | Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay | 2021 | Cell reports, 04-27, Volume: 35, Issue:4
| A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome. |
| AID1347098 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347154 | Primary screen GU AMC qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
| Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1347090 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347101 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347089 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1346987 | P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5
| A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1346986 | P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5
| A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1802638 | Alkaline Phosphatase Inhibition Assay from Article 10.1111/cbdd.12861: \\Isonicotinohydrazones as inhibitors of alkaline phosphatase and ecto-5'-nucleotidase.\\ | 2017 | Chemical biology & drug design, 03, Volume: 89, Issue:3
| Isonicotinohydrazones as inhibitors of alkaline phosphatase and ecto-5'-nucleotidase. |
| AID1802637 | Ecto-5'-Nucleotidase Inhibition Assay from Article 10.1111/cbdd.12861: \\Isonicotinohydrazones as inhibitors of alkaline phosphatase and ecto-5'-nucleotidase.\\ | 2017 | Chemical biology & drug design, 03, Volume: 89, Issue:3
| Isonicotinohydrazones as inhibitors of alkaline phosphatase and ecto-5'-nucleotidase. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |